175 results about "Coxsackie Viruses" patented technology

The invention provides a three-color fluorescent RT-PCR (Reverse Transcription-Polymerase Chain Reaction) combined detection method of enterovirus 71, Coxsackie virus A16 and other subtypes of enterovirus as well as a kit thereof. The method can rapidly and accurately detect the enterovirus 71, the Coxsackie virus A16 and the other subtypes of nucleic acids of enterovirus in a sample. The method comprises the following steps of: (1) acquiring and conveying a sample of an infected patient or a suspected patient; (2) preprocessing the sample and extracting RNA; (3) detecting the sample by adopting a one-step PCR-three-color fluorescent probe in-vitro amplification method; and (4) analyzing the corresponding sample according to the fluorescence intensity of each amplification reaction after the amplification reaction is finished, thereby judging the existence of the enterovirus 71, the Coxsackie virus A16 and the other subtypes of nucleic acids of the enterovirus in the acquired sample and being capable of carrying out accurate quantitation (a figure 3) on the enterovirus 71, the Coxsackie virus A16 and the other subtypes of nucleic acids of the enterovirus. The invention realizes the aim of carrying out rapid and accurate combined detection of the enterovirus 71, the Coxsackie virus A16 and the other subtypes of nucleic acids of the enterovirus.

The invention discloses a univalent and bivalent gene engineered subunit vaccine for preventing Enterovirus 71 (EV71) and Coxsackie virus A16 (Cox.A16) of hand-foot-and-mouth disease, and a preparation method thereof. The preparation method comprises the following steps: respectively obtaining recombinant baculovirus Bac-EV71-P1-3CD and Bac-Cox.A16-P1-3CD by gene engineering means, respectively efficiently coexpressing similar SeQ ID No.1 EV71 P1 and Se Q ID No.2 Cox.A16 P1 and 3CD proteins in insect cells, and respectively self-assembling into EV71 VLP and Cox.A16 VLP; establishing and verifying a vaccine strain third-stage seed lot library; culturing cells; inoculating and propagating virus; lysing the cells, ultra-filtering and purifying virus suspension; and further preparing the univalent and bivalent vaccine. The vaccine has good application prospect for preventing the hand-foot-and-mouth disease.

The invention discloses a preparation method for a recombinant coxsackie virus A16 like particle, which comprises the following steps: (1) cloning a P1 gene and a 3CD gene of a coxsackie virus A16 to a target plasmid to obtain a recombinant expression vector; (2) transforming a target yeast cell by using the recombinant expression vector obtained in the step (1) to obtain a recombinant yeast cellfor expressing the P1 gene and the 3CD gene; and (3) cracking the recombinant yeast cell obtained in the step (2), and separating to obtain the recombinant coxsackie virus A16 like particle. The recombinant coxsackie virus A16 like particle can be prepared in a yeast expression system by the method provided by the invention. Compared with a wild-type P1 gene and a wild-type 3CD gene, the yield ofthe coxsackie virus A16 like particle in the yeast expression system is greatly increased through the optimization of codons of the P1 gene and the 3CD gene, and the recombinant coxsackie virus A16 like particle can be further used for producing candidate preventive vaccines and pharmaceutical compositions for infant hand-foot-and-mouth diseases.

The invention provides a Coxsackie virus A16 virus strain, uses of the strain, a vaccine and a preparation method of the vaccine. The preservation number of the Coxsackie virus A16 virus strain is CGMCC No.6954. The CA16 virus strain has strong virulence, can be used for evaluating the CA16 vaccine, and can also be used for researching the CA16 virus infection mechanism. A method for establishing a Coxsackie virus A16 infected animal model provided by the invention can provide a stable animal model, and provides a foundation for the development of the Coxsackie virus A16 vaccine, the screening of antiviral drugs and the researches of the CA16 virus infection mechanism. The vaccine prepared by using the CA16 virus has effective immune activity.

The invention discloses a Coxsackie virus A6 strain (WF057R) and applications thereof. The preservation number of the Coxsackie virus A6 strain (WF057R) in China General Microbiological Culture Collection Center (CGMCC) is CGMCC No.13393. A vaccine and CVA6 antiserum prepared from WF057R can treat and prevent diseases caused by CVA6. Furthermore, the maternal-transferred antibody of WF057R also has a protective effect on newborn mice. WF057R can also be used to establish a stable Coxsackie virus A6 infected animal model with good repeatability, and the animal model can be applied to drug antivirus treatment and immune protective effect evaluation of viral inactivation vaccines.

The invention discloses a coxsackievirus A6 type infected animal model as well as a preparation method and an application thereof. The preparation method of the coxsackievirus A6 type infected animal model provided by the invention comprises a step of infecting an animal with an inactivated coxsackievirus A6 type strain, so that the coxsackievirus A6 type infected animal model is obtained, wherein the coxsackievirus A6 type strain is preserved in China General Microbiological Culture Collection Center with preservation number of CGMCC No.13393. The coxsackievirus A6 type infected animal model, which is stable and is good in repeatability, is constructed on the basis of the CVA6 strain WF057R; and with the application of the model, a research tool is provided for next medicine antiviral therapy and assessment of an immune protective effect of an inactivated viral vaccine.

The invention provides a compound shown in Formula I, an isomer, pharmaceutically-acceptable salt or solvate thereof, a preparation method thereof and application thereof in preparation of drugs for preventing and/or treating diseases caused by a Coxsackie virus. According to the invention, the compound keeps the activity of inhibiting the Coxsackie virus group B; and meanwhile, the pharmacokinetic parameters and safety of the compound drug are improved, thus indicating that the compound provided by the invention has favorable druggability and application prospects. The Formula I is shown in the specification.

A high-tilter coxsackievirus A10 domesticated strain TA151R-1 stable in passage is disclosed. The virus strain can infect RD cells, HEK293 cells, Vero cells, MRC-5 cells, Hep-2 cells, WI-38 cells, andother cell lines, and can be used for preparing a monovalent or polyvalent vaccine. The prepared vaccine can protect bodies from being harmed by coxsackievirus, can completely protect the body from attack by heterogenous viruses, can effectively prevent and/or treat diseases caused by coxsackievirus infection, and has a wide application prospect.

The present invention discloses a viral myocarditis gene vaccine, Said vaccine is constructed by using B3 type Coxsackie virus structural protein VPI gene and pcDNA carrier together, and its exterior is covered with a biological polysaccharide. It also discloses a method for preparing said gene vaccine and the application of said gene vaccine in preparation of medicine for preventing viral myocarditis.

The invention relates to a primer probe set used for detecting coxsackie viruses A6 type/A10 type/A16 type/enterovirus 71-type/enterovirus universal type through multiple PCR. The invention also provides a kit used for detecting coxsackie viruses A6 type/A10 type/A16 type/enterovirus 71-type/enterovirus universal type through multiple quantitative fluorescence PCR. The kit comprises the primer probe set. The above technical scheme provides a complete solution scheme for rapidly screening coxsackie viruses A6 type/A10 type/A16 type/enterovirus 71-type/enterovirus universal type in food, can increase emergent processing for hand-foot-and-mouth disease and comprehensive control capability, provides the necessary technical guarantee for reducing large-scope spreading of hand-foot-and-mouth disease in population, and eliminates the social influence and economic loss due to outbreak of infectious diseases.

The invention discloses a method for detecting a neutralizing antibody in coxsackievirus A6 (CV-A6), and a recombinant virus applied in the method. According to the method, the neutralizing antibody is detected by using a pseudovirus system packaged by two types of recombinant plasmids; by adopting a single-cycle infected pseudovirus, the safety problem caused by use of live viruses is avoided. The results of a plurality of tests prove that the pseudovirus detection system is a CV-A6 neutralizing antibody detection method which is safe, sensitive, rapid, specific, simple and convenient, and low in cost. Based on the characteristics, the pseudovirus detection system is very suitable for the tests for rapid and large-scale detection of the neutralizing antibody, and has an import applicationvalue for development of a CV-A6 viral vaccine and detection of CV-A6 specific neutralizing antibody level of patients and populations.

The invention relates to an N-substituted sophora flavescens olefine acid derivative represented by a general formula IA or IB, a preparation method thereof, a medicine composite containing the derivative, a method for utilizing the derivative to treat diseases caused by Coxsackie B viruses, and an application of the derivative to prepare a medicine for treating the diseases caused by the Coxsackie B viruses.

The invention relates to an isoflavone derivative and a preparation method and application thereof, which belong to the field of chemical medicaments. The technical problem solved by the invention is to provide the isoflavone derivative and the preparation and the application thereof. The isoflavone derivative has a structural formula as shown by (I), wherein R1 and R2 in the structural formula are C1-C5 alkyls. The isoflavone derivative has a significant effect of resisting Coxsackie viruses, can be used for preparing medicaments for resisting the Coxsackie viruses, and has an intensive application prospect.

The invention discloses a set of Coxsackie virus A16 (CA16) VP1 recombinant antigens which are prepared by respectively connecting 8 amino acids disclosed as SEQ ID NO.1-SEQ ID NO.8 with a flexible short peptide amino acid sequence. The invention also discloses monoclonal antibodies capable of being specifically combined with the CA16 VP1 recombinant antigens and application of the recombinant antigens in preparing an A16 Coxsackie virus antigen or antibody detection kit. The 8 recombinant antigens and 4 monoclonal antibodies have the characteristics of high sensitivity, high specificity and the like, and can be used as key raw materials for developing Coxsackie virus CA16 detection reagents.

The invention relates to a novel isothermal nucleic acid amplification technology, namely an isothermal multiple self-pairing triggering amplification technology (IMSA). According to the technology, amplification of a pathogeny gene can be realized under the condition of isothermality and under the action of a single functional enzyme without a thermal cycle instrument. The result determination of the isothermal multiple self-pairing triggering amplification technology (IMSA) can be realized by simple measures such as observing white precipitate of by-product magnesium pyrophosphate, adding a chromogenic agent and observing the color change before or after amplification. The most unique characteristic of the technology is that multiple oligonucleotide structures which can perform self-pairing and then trigger circular amplification will be generated during the process of amplification so that the triggering probability of following circular amplification is markedly increased, the amplification efficiency and detection sensitivity are promoted. On the basis of the isothermal multiple self-pairing triggering amplification technology (IMSA) we establish detection method of hand-foot-and-mouth disease pathogen coxsackievirus type A16 (CVA16) and human enterovirus type EV71 (EV71) VP1 gene, and rapid detection method of human influenza a virus H7N9 HA gene. By the application of the invention, simple, rapid, highly sensitive and highly specific detection can be realized.

The invention provides a fluorescent quantitative kit capable of detecting coxsackievirus type A2, A5. The fluorescent quantitative kit comprises a quantitative RT-PCR reactant liquor, an enzyme mixture solution, a primer probe mixture solution, CVA2 and CVA5 standard substances, CVA2 and CVA5 strong positive reference substances, CVA2 and CVA5 weak positive reference substances, and CVA2 and CVA5 negative reference substances. The one-step method real-time fluorescent quantitative RT-PCR technology is adopted, and the highly specific CVA2 and CVA5 primers and fluorescence labeling probes are used, so that the presence of CVA2 and CVA5 can be simultaneously detected from dejecta samples. Compared with the single fluorescent quantitative RT-PCR method, the fluorescent quantitative kit is quicker and more convenient, and the cost is saved. The fluorescent quantitative kit can detect the CVA2 and CVA5 in real time and accurately quantify the CVA2 and CVA5, so as to provide the early diagnosis for clinical, provide reference for the formulation of clinical treatment scheme. The fluorescent quantitative kit can be applied to experiment emergency diagnosis, quick screen and clinical diagnosis of outbreak caused by coxsackievirus type A2, A5, and can also be applied to epidemiologic research on hand-foot-mouth diseases.

The invention relates to the application of Shuqing granules in preparing medicine for resisting hand-foot-and-mouth disease pathogens, and belongs to traditional Chinese medicine field. The invention comprises the application of the Shuqing granules in preparing medicine for resisting hand-foot-and-mouth disease pathogens, the application of the Shuqing granules in preparing medicine for resisting enterovirus 71 and the application of the Shuqing granules in preparing medicine for resisting coxsackievirus A16. The invention proves that Shuqing granules has an effect of treating the hand-foot-and-mouth disease, and provides the scientific basis for promoting traditional antiviral Chinese medicine and effectively preventing and treating the hand-foot-and-mouth disease.

The present invention discloses one kind of immune globulin and its preparation and application. The immune globulin is type-70 enterovirus resisting and type-A24 Coxsachie virus resisting chicken yolk immune globulin and is prepared into product with antibody activity. The refined effective component has high purity and high activity, and is ideal product for eye drop and eye ointment. The immune globulin is used in preparing medicine for preventing and treating acute haemorrhagic conjunctivitis caused by type-70 enterovirus and type-A24 Coxsachie virus infection, and the medicine has high specificity, high curative rate and effect superior to conventional medicine.

The invention belongs to the technical field of recombinant virus genetic engineering, and in particular relates to a novel human enterovirus 71 (EV71)-coxackievirus A16 (CA16)-recombinant type 3 adenovirus (Had 3) candidate vaccine strain using recombinant human type 3 adenovirus as a vector, and a preparation method of the strain; hexon of the human type 3 adenovirus is simultaneously interpolated with a neutralizing epitope SP70 of the EV71 and a neutralizing epitope VP1-1 of the CA16, wherein the amino acid sequence of the neutralizing epitope SP70 of the EV71 is shown as YPTFGEHKQEKDLEYC and the amino acid sequence of the neutralizing epitope VP1-1 of the CA16 is shown as PKPTSRDSFAWQTAT. The recombinant human type 3 adenovirus is capable of simultaneously preventing EV71 and CA16, and the adenovirus has a significant effect on preventing hand-foot-and-mouth disease.

The invention discloses application of a bupleurum chinense extract in treatment of viral pneumonia, and relates to the technical field of traditional Chinese medicines. The invention discloses application of the bupleurum chinense extract in preparation of a medicine for treating viral pneumonia. The bupleurum tenuifolium extract has a relatively strong inhibition effect on viruses, has a lower usage amount, can be used for treating pneumonia caused by influenza A viruses, human rhinoviruses, human adenoviruses, common coronaviruses, coxsackie viruses or parainfluenza viruses, and is ineffective to viral pneumonia caused by herpes simplex viruses and human metapneumoviruses. A new strategy is provided for treating viral pneumonia.